BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
6.78
+0.03 (0.44%)
At close: Jan 14, 2026, 4:00 PM EST
6.79
+0.01 (0.15%)
After-hours: Jan 14, 2026, 7:58 PM EST
BioCryst Pharmaceuticals Market Cap
BioCryst Pharmaceuticals has a market cap or net worth of $1.43 billion as of January 14, 2026. Its market cap has decreased by -10.73% in one year.
Market Cap
1.43B
Enterprise Value
1.90B
1-Year Change
-10.73%
Ranking
Category
Stock Price
$6.78
Market Cap Chart
Since December 1, 1998, BioCryst Pharmaceuticals's market cap has increased from $100.40M to $1.43B, an increase of 1,321.80%. That is a compound annual growth rate of 10.28%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 13, 2026 | 1.42B | -13.46% |
| Dec 31, 2025 | 1.64B | 5.43% |
| Dec 31, 2024 | 1.56B | 26.96% |
| Dec 29, 2023 | 1.23B | -42.68% |
| Dec 30, 2022 | 2.14B | -14.12% |
| Dec 31, 2021 | 2.49B | 89.46% |
| Dec 31, 2020 | 1.32B | 245.25% |
| Dec 31, 2019 | 381.00M | -56.94% |
| Dec 31, 2018 | 884.80M | 83.11% |
| Dec 29, 2017 | 483.20M | 3.49% |
| Dec 30, 2016 | 466.90M | -38.31% |
| Dec 31, 2015 | 756.80M | -13.40% |
| Dec 31, 2014 | 873.90M | 94.59% |
| Dec 31, 2013 | 449.10M | 522.02% |
| Dec 31, 2012 | 72.20M | -35.36% |
| Dec 30, 2011 | 111.70M | -51.92% |
| Dec 31, 2010 | 232.30M | -7.38% |
| Dec 31, 2009 | 250.80M | 378.63% |
| Dec 31, 2008 | 52.40M | -77.65% |
| Dec 31, 2007 | 234.50M | -30.60% |
| Dec 29, 2006 | 337.90M | -23.72% |
| Dec 30, 2005 | 443.00M | 252.71% |
| Dec 31, 2004 | 125.60M | 3.37% |
| Dec 31, 2003 | 121.50M | 614.71% |
| Dec 31, 2002 | 17.00M | -75.61% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 961.00B |
| Johnson & Johnson | 526.55B |
| AbbVie | 392.16B |
| UnitedHealth Group | 303.42B |
| AstraZeneca | 299.25B |
| Novartis AG | 278.73B |
| Merck & Co. | 275.53B |
| Novo Nordisk | 262.20B |